Compare Organon & Co. Common Stock (OGN) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Otis Worldwide Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Otis Worldwide Corp trades at $69.77 (market cap $25.76B). The key difference: Otis Worldwide Corp is far larger — about 7.1× Organon & Co. Common Stock's market cap, and Otis Worldwide Corp pays the higher dividend (2.6%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Otis Worldwide Corp for 66 Days on average.
| OGN | OTIS | |
|---|---|---|
Market Cap | $3.62B | $25.76B |
Volume | 2,892,999 | 6,407,907 |
Sector | Health | Industrials |
52-Week High | $13.81 | $93.62 |
52-Week Low | $5.70 | $64.05 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $11.04B | $33.80B |
Dividend Yield | 0.58% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Otis Worldwide trades at $69.11, up 3.54% today but near its 52-week low amid bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B with a 10.17% net margin, though service margins face pressure from labor costs. Analyst consensus is mixed with a $87 price target, while institutional investors show varied positioning through recent acquisitions and sales.
The stock presents a defensive opportunity given its dominant elevator service franchise, but near-term upside is limited by margin pressures and China demand uncertainty. Key risks include execution on service margin expansion and macroeconomic headwinds affecting new equipment orders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
